There were 463 press releases posted in the last 24 hours and 158,410 in the last 365 days.

Cannabis Science Targets Rapid Expansion as it Opens New Negotiations for over 1,000 Acres Targeting Property/Drug Development in California and Nevada as Industry Opens Up

/EINPresswire.com/ -- IRVINE, CA--(Marketwired - Nov 10, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is prepared to move in on new opportunities in California and Nevada markets following the election cycle. The Company is now targeting over 1,000 acres in California and Nevada for property and drug development programs. The post-election plan includes new products, new dispensaries, and new strategic agreements.

"After closing the last land deal we announced for over 300 acres, we are now on to something much larger on a combined scale. This land package goes right in line with our other large deals in California and Nevada. These land deals put us in a very favorable position for high growth moving forward.  Coupled with completing our in-house laboratory, new drug programs, and our new website, we have some very exciting developments coming in the near future and we feel ready to meet the demands of more patients than ever before, and the timing couldn't be better. With the tremendous support for Proposition 64 and other pro-cannabis initiatives across the nation Cannabis Science is positioned to become a market leader," said Director, President, CEO & Co-Founder, Raymond C. Dabney.

Both California and Nevada voted to legalize marijuana for recreational adult use, which carries a host of benefits for Cannabis Science, as it allows more pathways for customers to attain the company's products. Considering that California alone has the sixth largest economy in the world in terms of GDP, this opens a very large market for the company to reach.

Recently, articles have been released stating that cannabis sales in Colorado are slated to exceed alcohol sales only a couple of years' post-legislation. In California's much larger market, this type of consumer support in the cannabis industry has huge potential to drive Cannabis Science's bottom line.

In preparation, the company has been rapidly expanding its drug development land deals in order to produce more products and meet demand increases. Additionally, the company is negotiating distribution deals with new dispensaries across the state to cast a wider net and reach more patients. The company's most recent new products, including a pain relief product, an immune system bolsterer, and a sleep aid, are very accessible, even to first-time patients.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
teresa@cannabisscience.com
Tel: 1-888-263-0832

Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832